Agilent Technologies stock (US00846U1016): Q1 earnings miss and updated guidance

Agilent Technologies reported Q1 2026 EPS of $1.36, missing estimates by $0.01, with revenue at $1.80 billion. The company issued Q2 guidance amid a recent 0.1% stock dip.

Agilent Technologies Inc. released its Q1 2026 earnings on February 25, 2026, reporting earnings per share of $1.36, which fell short of the consensus estimate of $1.37 by $0.01, MarketBeat as of 05/08/2026. Quarterly revenue increased 7.0% year-over-year to $1.80 billion, slightly below the expected $1.81 billion. The company also provided Q2 2026 guidance with EPS of $1.39-$1.42 versus consensus $1.40, and revenue at $1.8 billion.

Agilent Technologies stock traded down 0.1% recently, closing at $115.52 on May 8, 2026, on NYSE, MarketBeat as of 05/11/2026. Crossmark Global Holdings Inc. acquired 9,615 shares of the company. This comes as US investors monitor life sciences and diagnostics firms amid sector volatility.

As of: 11.05.2026

By the editorial team – specialized in equity coverage.

At a glance

• Name: Agilent Technologies, Inc.
• Sector/industry: Life Sciences & Diagnostics
• Headquarters/country: United States
• Core markets: North America, Europe, Asia
• Key revenue drivers: Instruments, consumables, services
• Home exchange/listing venue: NYSE (A)
• Trading currency: USD

Agilent Technologies Inc.: core business model

Agilent Technologies Inc. develops and sells life sciences, diagnostics, and applied chemical markets instruments and related consumables, software, and services worldwide. The company operates through three segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. Products include atomic spectroscopy, circulator chromatography systems, and mass spectrometry instruments. This model supports US investors via exposure to biotech R&D and healthcare diagnostics growth.

Trailing twelve-month revenue stood at $6.95 billion with net income of $1.30 billion as of the latest reported period ending before Q1 2026 earnings published February 25, 2026, per MarketBeat as of 05/08/2026. Trailing EPS was $4.53, with a P/E ratio of 25.50.

Main revenue and product drivers for Agilent Technologies Inc.

The Life Sciences and Applied Markets segment drives revenue through chromatography and mass spectrometry systems used in pharmaceuticals and food safety testing. Diagnostics and Genomics offers reagents for clinical diagnostics, while Agilent CrossLab provides maintenance services. These areas benefit from steady demand in US healthcare and research sectors.

For Q1 2026 reported February 25, 2026, revenue grew 7.0% to $1.80 billion. Annual revenue for the prior full year was $6.95 billion, highlighting recurring consumables as a stable driver for US market participants.

Industry trends and competitive position

The life sciences tools sector sees growth from precision medicine and biopharma R&D, with Agilent holding a strong position via innovative spectroscopy tech. Competitors include Thermo Fisher and Danaher. Agilent's 50-day moving average of $115.99 and 200-day of $131.97 reflect market dynamics as of data published May 11, 2026, MarketBeat as of 05/11/2026.

Why Agilent Technologies Inc. matters for US investors

Listed on NYSE, Agilent Technologies provides US investors direct access to the $50+ billion global analytical instruments market, with significant revenue from North American pharma and biotech. Its tools support FDA-regulated drug development, tying performance to US economic health in healthcare innovation.

Conclusion

Agilent Technologies Inc. showed mixed Q1 2026 results with an EPS miss but revenue growth and steady Q2 guidance. Institutional interest persists, as seen in recent share acquisitions, while the stock navigates sector trends. US investors track these updates for insights into life sciences demand. Financial metrics like debt-to-equity of 0.44 remain solid.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.